Residues Leu261, Trp264, and Phe265 account for apolipoprotein E-induced dyslipidemia and affect the formation of apolipoprotein E-containing high-density lipoprotein

Biochemistry

Volumn 46, Issue 33, 2007, Pages 9645-9653

  Drosatos, Konstantinos ^a,b   Kypreos, Kyriakos E ^a   Zannis, Vassilis I ^a,b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CRETE   (Greece)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CHOLESTEROL; ELECTRON MICROSCOPY; GENE TRANSFER; LIPIDS; SUBSTITUTION REACTIONS; VIRUSES;

HIGH-DENSITY LIPOPROTEIN (HDL); HYPERTRIGLYCERIDEMIA; VERY LOW-DENSITY LIPOPROTEIN (VLDL);

PROTEINS;

APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MUTANT PROTEIN; VERY LOW DENSITY LIPOPROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

ADENOVIRIDAE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; CHOLESTEROL; HUMANS; HYPERTRIGLYCERIDEMIA; LEUCINE; LIPOPROTEINS, HDL; MICE; MICE, MUTANT STRAINS; MOLECULAR SEQUENCE DATA; MUTATION; PHENYLALANINE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RECOMBINANT PROTEINS; TRYPTOPHAN;

ADENOVIRIDAE; MUS;

EID: 34548058083     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi700232g     Document Type: Article

References (33)

1. Zannis, V. I., Kypreos, K. E., Chroni, A., Kardassis, D., and Zanni, E. E. (2004) in Molecular Mechanisms of Atherosclerosis (Loscalzo, J., Ed.) pp 111-174, Taylor & Francis, New York.
2. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., and Pericak-Vance, M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science 261, 921-923.
3. Zannis, V. I., Zanni, E. E., Makrides, S. C., Kardassis, D., and Aleshkov, S. (1998) in NATO AS1 Series, Life Sciences (Catravas, J. D., Ed.) pp 179-209, Plenum Press, New York.
4. Plump, A. S., Smith, J. D., Hayek, T., Aalto-Setala, K., Walsh, A., Verstuyft, J. G., Rubin, E. M., and Breslow, J. L. (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells, Cell 71, 343-353.
5. Schaefer, E. J., Gregg, R. E., Ghiselli, G., Forte, T. M., Ordovas, J. M., Zech, L. A., and Brewer, H. B., Jr. (1986) Familial apolipoprotein E deficiency, J. Clin. Invest. 78, 1206-1219.
6. Kypreos, K. E., and Zannis, V. I. (2006) LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice, J. Lipid Res. 47, 521-529.
7. Linton, M. F., and Fazio, S. (1999) Macrophages, lipoprotein metabolism, and atherosclerosis: Insights from murine bone marrow transplantation studies, Curr. Opin. Lipidol. 10, 97-105.
8. Hasty, A. H., Linton, M. F., Brandt, S. J., Babaev, V. R., Gleaves, L. A., and Fazio, S. (1999) Retroviral gene therapy in ApoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation, Circulation 99, 2571-2576.
9. Thorngate, F. E., Rudel, L. L., Walzem, R. L., and Williams, D. L. (2000) Low levels of extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercholesterolemia in ApoE-deficient mice, Arterioscler. Thromb. Vasc. Biol. 20, 1939-1945.
10. Shimano, H., Ohsuga, J., Shimada, M., Namba, Y., Gotoda, T., Harada, K., Katsuki, M., Yazaki, Y., and Yamada, N. (1995) Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall, J. Clin. Invest. 95, 469-476.
11. Tsukamoto, K., Tangirala, R., Chun, S. H., Pure, E., and Rader, D. J. (1999) Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice, Arterioscler. Thromb. Vasc. Biol. 19, 2162-2170.
12. Tsukamoto, K., Tangirala, R. K., Chun, S., Usher, D., Pure, E., and Rader, D. J. (2000) Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice, Mol. Ther. 1, 189-194.
13. Raffai, R. L., Loeb, S. M., and Weisgraber, K. H. (2005) Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels, Arterioscler. Thromb. Vasc. Biol. 25, 436-441.
14. Huang, Y., von Eckardstein, A., Wu, S., Maeda, N., and Assmann, G. (1994) A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells, Proc. Natl. Acad. Sci. U.S.A. 91, 1834-1838.
15. Remaley, A. T., Stonik, J. A., Demosky, S. J., Neufeld, E. B., Bocharov, A. V., Vishnyakova, T. G., Eggerman, T. L., Patterson, A. P., Duverger, N. J., Santamarina-Fojo, S., and Brewer, H. B., Jr. (2001) Apolipoprotein specificity for lipid efflux by the human ABCAI transporter, Biochem. Biophys. Res. Commun. 280, 818-823.
16. Kypreos, K. E., Van Dijk, K. W., van Der, Z. A., Havekes, L. M., and Zannis, V. I. (2001) Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion, J. Biol. Chem. 276, 19778-19786.
17. Kypreos, K. E., Li, X., Van Dijk, K. W., Havekes, L. M., and Zannis, V. I. (2003) Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype, Biochemistry 42, 9841-9853.
18. Zannis, V. I., Chroni, A., Kypreos, K. E., Kan, H. Y., Cesar, T. B., Zanni, E. E., and Kardassis, D. (2004) Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer, Curr. Opin. Lipidol. 15, 151-166.
19. Huang, Y., Liu, X. Q., Rall, S. C., Jr., Taylor, J. M., von Eckardstein, A., Assmann, G., and Mahley, R. W. (1998) Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia, J. Biol. Chem. 273, 26388-26393.
20. Havel, R. J., Kotite, L., Vigne, J. L., Kane, J. P., Tun, P., Phillips, N., and Chen, G. C. (1980) Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. Concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency, J. Clin. Invest. 66, 1351-1362.
21. Kypreos, K. E., Morani, P., Van Dijk, K. W., Havekes, L. M., and Zannis, V. I. (2001) The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice, Biochemistry 40, 6027-6035.
22. Kypreos, K. E., Van Dijk, K. W., Havekes, L. M., and Zannis, V. I. (2005) Generation of a recombinant apolipoprotein E variant with improved biological functions: Hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia, J. Biol. Chem. 280, 6276-6284.
23. Liu, T., Krieger, M., Kan, H. Y., and Zannis, V. I. (2002) The effects of mutations in helices 4 and 6 of apoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport, J. Biol. Chem. 277, 21576-21584.
24. Chroni, A., Kan, H. Y., Kypreos, K. E., Gorshkova, I. N., Shkodrani, A., and Zannis, V. I. (2004) Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice, Biochemistry 43, 10442-10457.
25. He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., and Vogelstein, B. (1998) A simplified system for generating recombinant adenoviruses, Proc. Natl. Acad. Sci. U.S.A. 95, 2509-2514.
26. Fallaux, F. J., Kranenburg, O., Cramer, S. J., Houweling, A., Van Ormondt, H., Hoeben, R. C., and van der Eb, A. J. (1996) Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors, Hum. Gene Ther. 7, 215-222.
27. Li, X., Kypreos, K., Zanni, E. E., and Zannis, V. (2003) Domains of apoE required for binding to apoE receptor 2 and to phospholipids: Implications for the functions of apoE in the brain, Biochemistry 42, 10406-10417.
28. Chroni, A., Liu, T., Gorshkova, I., Kan, H. Y., Uehara, Y., von Eckardstein, A., and Zannis, V. I. (2003) The central helices of apoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wildtype apoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo, J. Biol. Chem. 278, 6719-6730.
29. Chroni, A., Kan, H. Y., Shkodrani, A., Liu, T., and Zannis, V. I. (2005) Deletions of Helices 2 and 3 of Human ApoA-I Are Associated with Severe Dyslipidemia following Adenovirus-Mediated Gene Transfer in ApoA-I-Deficient Mice, Biochemistry 44, 4108-4117.
30. Zhao, Y., Thorngate, F. E., Weisgraber, K. H., Williams, D. L., and Parks, J. S. (2005) Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase (LCAT) on apolipoprotein B lipoproteins, Biochemistry 44, 1013-1025.
31. Zannis, V. I., Chroni, A., and Krieger, M. (2006) Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL, J. Mol. Med. 84, 276-294.
32. Yuhanna, I. S., Zhu, Y., Cox, B. E., Hahner, L. D., Osborne-Lawrence, S., Lu, P., Marcel, Y. L., Anderson, R. G., Mendelsohn, M. E., Hobbs, H. H., and Shaul, P. W. (2001) High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase, Nat. Med. 7, 853-857.
33. Rader, D. J. (2002) High-density lipoproteins and atherosclerosis, Am. J. Cardiol. 90, 62i-70i.